IGFBP7 and acute kidney injury: Currently, there are no data to support the premise that early recognition of kidney injury with the [TIMP-2]•[IGFBP7] test or other AKI biomarkers prevents the progression of AKI or is associated with a cost-benefit to the patient or institution [41].